SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences (MRVI) company and global provider of life science reagents and services, has launched its newest ...
TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when ...
New all-in-one IVT kit can deliver up to 2X more mRNA and up to 85% lower dsRNA compared to other kits on the market through streamlined mRNA synthesis with efficient capping, increased yield, reduced ...
In vitro transcribed mRNA has lived up to its potential as a game-changing disruptive vaccine modality during the COVID-19 ...
As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.
The market for mRNA vaccines has experienced a surge fueled by the global rollout of the COVID-19 vaccines, and the potential of mRNA technology in public health opens a new frontier in medical ...
In this valuable study, the authors develop new approaches to investigate mRNA imprinting, a phenomenon in which RNA-protein complexes form in the nucleus to influence the fate of transcripts in the ...
Through this agreement, Quantoom will be able to integrate TriLink’s CleanCap® mRNA capping technology into its Ntensify® platform, facilitating effective RNA synthesis and wider distribution of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results